Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Drug Delivery Devices, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Table of Contents

1 Technology Definition
1.1 Inclusion and Exclusion Criteria
1.1.1 Inclusions
1.1.2 Exclusions

2 Research Scope

3 Key Questions Answered in the Report

4 Research Methodology
4.1 Cell and Gene Therapy Drug Delivery Devices: Research Methodology
4.2 Primary Data Sources
4.3 Secondary Data Sources
4.4 Market Estimation Model
4.5 Criteria for Company Profiling

5 Market Overview
5.1 Introduction
5.2 Cell and Gene Therapies and Drug Delivery Devices Industry
5.3 Cell and Gene Therapy Drugs and Their Clinical Importance
5.4 Cell and Gene Therapy Drug Delivery Devices Market: Current Scenario
5.5 Cell and Gene Therapy Drug Delivery Devices Market: Future Perspective

6 Global Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential, 2020-2030
6.1 Overview
6.2 Pipeline Analysis
6.2.1 Drug Delivery Systems in Development: Current Scenario
6.2.1.1 Ongoing Clinical Trials of Drug Delivery Systems
6.2.1.2 Limitations of Cell and Gene Therapy Drug Delivery Devices
6.2.1.3 Recent Advancements in Gene Therapy Drug Delivery
6.3 Cell and Gene Therapy Drug Delivery Devices Market and Growth Potential
6.4 Cell and Gene Therapy Drug Development and Commercialization Landscape
6.5 Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices Market
6.5.1 Impact of COVID-19 on Global Cell and Gene Therapy Drug Delivery Devices Market Growth Rate
6.5.2 Impact of COVID-19 on Supply Chain of Cell and Gene Therapy Drug Delivery Devices Market
6.5.3 Clinical Trial Disruptions and Resumptions

7 Emerging Technology Landscape
7.1 Potential Technologies in Cell and Gene Therapy Drug Delivery Devices Market
7.2 Microchip Technology
7.3 Nanotechnology-Based Drug Delivery Devices
7.4 Lipid Nanoparticles in Gene Therapy

8 Market Dynamics
8.1 Impact Analysis
8.2 Market Drivers
8.2.1 Increasing Prevalence of Cancer and Chronic Diseases
8.2.2 Increased Funding of Cell and Gene Therapies
8.2.3 Rising Number of FDA Approvals of Cell and Gene Therapies, and Clinical Trials
8.3 Market Restraints
8.3.1 Stringent Legal Requirements and Regulations
8.3.2 Injuries and Infections Caused by Needles
8.4 Market Opportunities
8.4.1 Strong Pipeline of Cell and Gene Therapies

9 Industry Insights
9.1 Regulatory Scenario of Cell and Gene Therapy Drug Delivery Devices Market
9.1.1 Overview
9.1.2 Risk Assessment of Medical Devices
9.1.3 Regulation of Medical Devices in the U.S.
9.1.3.1 Food and Drug Administration (FDA)
9.1.3.2 Food and Drug Administration (FDA) Regulations Modification
9.1.4 Regulation of Medical Devices in Europe
9.1.4.1 Regulations in Europe – Highlights
9.1.4.2 EU Regulatory Pathway for Medical Device
9.1.4.3 Federal Agencies of EU Member States
9.1.4.4 European Commission Regulations Modification
9.1.5 Regulation of Medical Devices in Asia-Pacific
9.1.5.1 Overview
9.1.5.2 Regulatory and Market Access Challenges in Asia-Pacific
9.1.5.3 Regulatory Environment for Medical Devices in China
9.2 Pricing and Reimbursement of Cell and Gene Therapy Drug Delivery Devices

10 Patent Landscape

11 Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type)
11.1 Overview
11.2 Subretinal Injection Cannula
11.3 Extension Tube
11.4 Intravenous Catheter
11.5 Sterile Insulin Syringe
11.5.1 Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle)
11.5.2 Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle)
11.6 Pre-Filled Syringe
11.6.1 Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle)
11.6.2 Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle)
11.7 Infusion Bags
11.7.1 Infusion Bags (Size 10 ML to 50 ML)
11.7.2 Infusion Bags (Size 68 ML)
11.7.3 Infusion Bags (Size 60 ML)
11.7.4 Infusion Bags (Size Up to 65 ML)

12 Global Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Drugs)
12.1 Commercialized Drugs
12.1.1 Luxturna
12.1.2 Kymriah
12.1.3 Provenge
12.1.4 Zolgensma
12.1.5 Yescarta
12.1.6 Strimvelis

13 Global Cell and Gene Therapy Drug Delivery Devices Market (by Region)
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.1.1 Approved Products
13.2.1.2 Market Size and Forecast
13.2.1.3 Key Developments
13.2.2 Canada
13.2.2.1 Approved Products
13.2.2.2 Market Size and Forecast
13.2.2.3 Key Developments
13.3 Europe
13.3.1 Germany
13.3.1.1 Approved Products
13.3.1.2 Market Size and Forecast
13.3.1.3 Key Developments
13.3.2 France
13.3.2.1 Approved Products
13.3.2.2 Market Size and Forecast
13.3.2.3 Key Developments
13.3.3 U.K.
13.3.3.1 Approved Products
13.3.3.2 Market Size and Forecast
13.3.4 Italy
13.3.4.1 Approved Products
13.3.4.2 Market Size and Forecast
13.3.4.3 Key Developments
13.3.5 Spain
13.3.5.1 Approved Products
13.3.5.2 Market Size and Forecast
13.3.5.3 Key Developments
13.3.6 Netherlands
13.3.6.1 Approved Products
13.3.6.2 Market Size and Forecast
13.3.6.3 Key Developments
13.3.7 Russia
13.3.7.1 Approved Products
13.3.7.2 Market Size and Forecast
13.3.8 Rest-of-Europe
13.3.8.1 Market Size and Forecast
13.3.8.2 Key Developments
13.4 Asia-Pacific
13.4.1 Japan
13.4.1.1 Approved Products
13.4.1.2 Market Size and Forecast
13.4.1.3 Key Developments
13.4.2 China
13.4.2.1 Approved Products
13.4.2.2 Market Size and Forecast
13.4.2.3 Key Developments
13.4.3 Australia
13.4.3.1 Approved Products
13.4.3.2 Market Size and Forecast
13.4.3.3 Key Developments
13.4.4 South Korea
13.4.4.1 Approved Products
13.4.4.2 Market Size and Forecast
13.4.4.3 Key Developments
13.4.5 India
13.4.5.1 Approved Products
13.4.6 Singapore
13.4.6.1 Market Size and Forecast
13.4.6.2 Key Developments
13.4.7 Rest-of-Asia-Pacific
13.4.7.1 Market Size and Forecast
13.4.7.2 Key Developments
13.5 Latin America
13.5.1 Brazil
13.5.1.1 Market Size and Forecast
13.5.2 Mexico
13.5.2.1 Market Size and Forecast
13.5.3 Rest-of-Latin America
13.5.3.1 Market Size and Forecast
13.6 Rest-of-World
13.6.1 Market Size and Forecast

14 Competitive Landscape
14.1 Key Developments and Strategies
14.1.1 Overview
14.1.2 Regulatory and Legal Developments
14.1.3 Synergistic Activities
14.1.4 M&A Activities
14.1.5 Funding Activities
14.2 Market Share Analysis

15 Company Profiles
15.1 Overview
15.2 Amgen Inc.
15.2.1 Company Overview
15.2.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.2.3 Financials
15.2.4 R&D Expenditure, 2017-2019
15.2.5 SWOT Analysis
15.3 Bausch & Lomb Incorporated.
15.3.1 Company Overview
15.3.2 Role of Bausch & Lomb Incorporated., in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.3.3 Financials
15.3.4 Key Insights About Financial Health of the Company
15.3.5 SWOT Analysis
15.4 Becton, Dickinson and Company
15.4.1 Company Overview
15.4.2 Role of Becton, Dickinson and Company in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.4.3 Financials
15.4.4 Key Insights About Financial Health of the Company
15.4.5 SWOT Analysis
15.5 Bluebird bio, Inc.
15.5.1 Company Overview
15.5.2 Role of Bluebird bio, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.5.3 Financials
15.5.4 R&D Expenditure, 2017-2019
15.5.5 SWOT Analysis
15.6 Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
15.6.1 Company Overview
15.6.2 Role of Castle Creek Biosciences, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.6.3 Key Insights About Financial Health of the Company
15.6.4 SWOT Analysis
15.7 Dendreon Pharmaceuticals LLC.
15.7.1 Company Overview
15.7.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.7.3 SWOT Analysis
15.8 Helixmith Co., Ltd (ViroMed Co., Ltd)
15.8.1 Company Overview
15.8.2 Role of Helixmith Co., Ltd. in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.8.3 Financials
15.8.4 SWOT Analysis
15.9 Human Stem Cells Institute
15.9.1 Company Overview
15.9.2 Role of Human Stem Cell Institute in Global Cell and Gene Therapy Drug Delivery Devices Market
15.9.3 SWOT Analysis
15.1 Kite Pharma, Inc.
15.10.1 Company Overview
15.10.2 Role of Kite Pharma, Inc in Global Cell and Gene Therapy Drug Delivery Devices Market
15.10.3 Financials
15.10.4 R&D Expenditure, 2017-2019
15.10.5 SWOT Analysis
15.11 Kolon TissueGene, Inc.
15.11.1 Company Overview
15.11.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.11.3 SWOT Analysis
15.12 Novartis AG
15.12.1 Company Overview
15.12.2 Role of Novartis AG in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.12.3 Financials
15.12.4 R&D Expenditure, 2017-2019
15.12.5 SWOT Analysis
15.13 Orchard Therapeutics plc.
15.13.1 Company Overview
15.13.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.13.3 Financials
15.13.4 SWOT Analysis
15.14 Pfizer, Inc.
15.14.1 Company Overview
15.14.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.14.3 Financials
15.14.4 R&D Expenditure, 2017-2019
15.14.5 SWOT Analysis
15.15 Renova Therapeutics
15.15.1 Company Overview
15.15.2 Role of Renova Therapeutics in Global Cell and Gene Therapy Drug Delivery Devices Market
15.15.3 SWOT Analysis
15.16 Spark Therapeutics, Inc.
15.16.1 Company Overview
15.16.2 Role of Spark Therapeutics, Inc. in Global Cell and Gene Therapy Drug Delivery Devices Market
15.16.3 Financials
15.16.4 Key Insights About Financial Health of the Company
15.16.5 SWOT Analysis
15.17 uniQure N.V.
15.17.1 Company Overview
15.17.2 Role of uniQure N.V. in Global Cell and Gene Therapy Drug Delivery Devices Market
15.17.3 SWOT Analysis
15.18 Vericel Corporation
15.18.1 Company Overview
15.18.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Drug Delivery Devices Market
15.18.3 Financials
15.18.4 Key Insights About Financial Health of the Company
15.18.5 SWOT Analysis

List of Tables 
Table 1: Evolution of Controlled Drug Delivery Systems: 30 Years (2000-2030)
Table 5.1: Drug Delivery Methods of Cell and Gene Therapeutics
Table 5.2: Commercialized Drugs of Cell and Gene Therapy Drug Delivery Devices Market, Device Size and Specification
Table 5.3: Comparison of Major Routes of Drug Delivery for Systemic Absorption
Table 6.1: Ongoing Clinical Trials of Drug Delivery Systems
Table 6.2: Commercialized Drugs of Cell and Gene Therapy Drug Delivery Devices Market
Table 7.1: Pipeline Drug Delivery Devices for Cell and Gene Therapy
Table 7.2: Drug Delivery Based on Lab-on-a-Chip Technology
Table 7.3: Nanomaterials and Nanobiotechnologies used for Drug Delivery
Table 7.4: Globally Approved Lipid Nanoparticles Therapies
Table 8.1: Commercialized Cell and Gene Therapies in the Market
Table 8.2: Filing Requirements for Pre-Filled Syringes
Table 8.3: Differentiation of an Injectable Therapeutic Throughout its Life Cycle
Table 9.1: European Commission Medical Device Directives
Table 9.2: Federal Agencies of EU Member States
Table 9.3: Key Market Access Landscape (9 Countries), January 2019
Table 9.4: Average Selling Price of Cell and Gene Therapy Drug Delivery Devices, (2019 and 2030)
Table 10.1: Patents for Cell and Gene Therapy Drug Delivery Devices
Table 13.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA

List of Figures 
Figure 1: Global Geriatric Population by Age
Figure 2: Global Cell and Gene Therapy Drug Delivery Devices Market Snapshot
Figure 3: Dominant Segments of the Global Cell and Gene Therapy Drug Delivery Devices Market, 2019 and 2030
Figure 4: Global Cell and Gene Therapy Drug Delivery Devices Market (by Product Type), 2019 and 2030
Figure 5: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region), 2019 and 2030
Figure 6: Global Cell and Gene Therapy Drug Delivery Devices: Impact Analysis
Figure 7: Leading Players in Global Cell and Gene Therapy Drug Delivery Devices Market
Figure 2.1: Global Cell and Gene Therapy Drug Delivery Devices Market Segmentation
Figure 4.1: Global Cell and Gene Therapy Drug Delivery Devices Market Methodology
Figure 4.2: Primary Research Methodology
Figure 4.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 4.4: Top-Down Approach (Segment-Wise Analysis)
Figure 5.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2018
Figure 6.1: Global Cell and Gene Therapy Drug Delivery Devices Market, $Thousand, 2019 and 2030
Figure 6.2: Cell and Gene Therapy Clinical Trials (by Phase)
Figure 6.3: Global Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 6.4: Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Products) 2019
Figure 6.5: Cell and Gene Therapy Drug Delivery Devices Market (by Commercialized Products), 2030
Figure 6.6: Most Impacted Practices in Cell and Gene Therapy Drug Delivery Devices Market
Figure 6.7: Impact of COVID-19 on Cell and Gene Therapy Drug Delivery Devices Market
Figure 6.8: Major Areas of Disruption
Figure 6.9: Impact of COVID-19 on Clinical Trials
Figure 6.10: Status of Clinical Trials (April 2020–July 2020)
Figure 6.11: Disrupted Clinical Trials (by Phase of Clinical Trial)
Figure 6.12: Disrupted Clinical Trials (by Therapy Area)
Figure 7.1: Interrelationship of Drug Delivery Devices, Pharmaceutical Industry, and Biotechnology
Figure 8.1: Global Cell and Gene Therapy Drug Delivery Devices: Impact Analysis
Figure 8.2: Total Burden of Diseases (by Cause), 2017
Figure 8.3: Number of Active and Completed Clinical Trials for Cell and Gene Therapy, 2014-2018
Figure 8.4: Total Percutaneous Injuries Reported by Drug Delivery Device
Figure 9.1: Risk Assessment of Medical Devices
Figure 9.2: FDA Regulatory Pathway for Medical Device
Figure 9.3: FDA Regulations Modification: Pre-COVID-19 Phase to Post-COVID-19 Phase
Figure 9.4: EU Regulatory Pathway for Medical Device
Figure 9.5: European Commission Regulations Modification: Pre-COVID-19 Phase to Post-COVID-19 Phase
Figure 9.6: Regulatory and Market Access Challenges in Asia-Pacific
Figure 9.7: Regulatory Environment for Medical Devices in China
Figure 9.8: Chinese Medical Device Classification and Pre-Market Requirement
Figure 10.1: Share of Patents (by Ownership), 2016-2019
Figure 11.1: Revenue Contribution of Different Segments, 2020 and 2030
Figure 11.2: Subretinal Injection Cannula (by Volume), 2019-2030
Figure 11.3: Subretinal Injection Cannula (by Value), 2019-2030
Figure 11.4: Extension Tube (by Volume), 2019-2030
Figure 11.5: Extension Tube (by Value), 2019-2030
Figure 11.6: Intravenous Catheter (by Volume), 2019-2030
Figure 11.7: Intravenous Catheter (by Value), 2019-2030
Figure 11.8: Revenue Contribution of Sterile Insulin Syringe Segments, 2019 and 2030
Figure 11.9: Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) (by Volume),  2019-2030
Figure 11.10: Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle) (by Value),  2019-2030
Figure 11.11: Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) (by Volume), 2019-2030
Figure 11.12: Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle) (by Value),  2019-2030
Figure 11.13: Revenue Contribution of Pre-Filled Syringe Segments, 2019 and 2030
Figure 11.14: Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) (by Volume),  2019-2030
Figure 11.15: Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle) (by Value),  2019-2030
Figure 11.16: Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) (by Volume),  2019-2030
Figure 11.17: Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle) (by Value),  2019-2030
Figure 11.18: Revenue Contribution of Infusion Bag Segments, 2019 and 2030
Figure 11.19: Infusion Bag (Size 10 ML to 50 ML) (by Volume), 2019-2030
Figure 11.20: Infusion Bag (Size 10 ML to 50 ML) (by Value), 2019-2030
Figure 11.21: Infusion Bag (68 ML) (by Volume), 2019-2030
Figure 11.22: Infusion Bag (68 ML) (by Value), 2019-2030
Figure 11.23: Infusion Bag (60 ML) (by Volume), 2019-2030
Figure 11.24: Infusion Bag (60 ML) (by Value), 2019-2030
Figure 11.25: Infusion Bag (Size Up to 65 ML) (by Volume), 2019-2030
Figure 11.26: Infusion Bag (Size Up to 65 ML) (by Value), 2019-2030
Figure 12.1: Luxturna Drug Delivery Devices (by Volume), 2019 and 2030
Figure 12.2: Luxturna Drug Delivery Devices (by Value), 2019 and 2030
Figure 12.3: Kymriah Drug Delivery Devices (by Volume), 2019 and 2030
Figure 12.4: Kymriah Drug Delivery Devices (by Value), 2019 and 2030
Figure 12.5: Provenge Drug Delivery Devices (by Volume), 2019 and 2030
Figure 12.6: Provenge Drug Delivery Devices (by Value), 2019 and 2030
Figure 12.7: Zolgensma Drug Delivery Devices (by Volume), 2019 and 2030
Figure 12.8: Zolgensma Drug Delivery Devices (by Value), 2019 and 2030
Figure 12.9: Yescarta Drug Delivery Devices (by Volume), 2019 and 2030
Figure 12.10: Yescarta Drug Delivery Devices (by Value), 2019 and 2030
Figure 12.11: Strimvelis Drug Delivery Devices (by Volume), 2019 and 2030
Figure 12.12: Strimvelis Drug Delivery Devices (by Value), 2019 and 2030
Figure 13.1: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region)
Figure 13.2: Global Cell and Gene Therapy Drug Delivery Devices Market (by Region), 2019 and 2030
Figure 13.3: North America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: U.S. Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.6: Projections of the Older Adult Population in the U.S.: 2016 to 2060 (Thousand)
Figure 13.7: Canada Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.8: Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.9: Europe-Market Dynamics
Figure 13.10: Germany Cell and Gene Therapy Drug Delivery Devices Market,  2019-2030
Figure 13.11: France Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.12: U.K. Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.13: Italy Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.14: Spain Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.15: Netherlands Cell and Gene Therapy Drug Delivery Devices Market,  2019-2030
Figure 13.16: Russia Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.17: Rest-of-Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.18: Europe Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.19: Asia-Pacific: Market Dynamics
Figure 13.20: Japan Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.21: China Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.22: Australia Cell and Gene Therapy Drug Delivery Devices Market,  2019-2030
Figure 13.23: South Korea Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.24: Singapore Cell and Gene Therapy Drug Delivery Devices Market,  2020-2030
Figure 13.25: Rest-of-Asia-Pacific Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.26: Latin America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.27: Latin America: Market Dynamics
Figure 13.28: Brazil Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.29: Mexico Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.30: Rest-of-Latin America Cell and Gene Therapy Drug Delivery Devices Market, 2019-2030
Figure 13.31: Rest-of-World Cell and Gene Therapy Drug Delivery Devices Market, 2020-2030
Figure 14.1: Share of Key Developments and Strategies, January 2016-January 2021
Figure 14.2: Regulatory and Legal Developments Share (by Company), January 2016-January 2021
Figure 14.3: Synergistic Activities (by Company), January 2016-January 2021
Figure 14.4: Company Share (by Synergistic Activity), January 2016-January 2021
Figure 14.5: M&A Activities Share (by Company), January 2016-January 2021
Figure 14.6: Funding Activities (by Company), January 2016-January 2021
Figure 14.7: Market Share Analysis for the Global Cell Therapy and Gene Drug Delivery Devices Market, 2019
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: Amgen Inc.: Overall Product Portfolio
Figure 15.3: Amgen Inc.: Pipeline Product Portfolio
Figure 15.4: Amgen, Inc.: Overall Financials, 2017-2019
Figure 15.5: Amgen, Inc.: Sales (by Product), 2017-2019
Figure 15.6: Amgen, Inc.: Revenue (by Region), 2017-2019
Figure 15.7: Amgen, Inc.: R&D Expenditure, 2017-2019
Figure 15.8: Amgen Inc.: SWOT Analysis
Figure 15.9: Product Portfolio: Bausch & Lomb Incorporated.,
Figure 15.10: Bausch & Lomb Incorporated.: Overall Financials, 2017-2019
Figure 15.11: Bausch & Lomb Incorporated.: R&D Expenditure, 2017-2019
Figure 15.12: Bausch & Lomb Incorporated.: SWOT Analysis
Figure 15.13: Becton, Dickinson and Company: Overall Financials, 2017-2019
Figure 15.14: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
Figure 15.15: Becton, Dickinson and Company: Revenue Split for BD Life Sciences, 2017-2019
Figure 15.16: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 15.17: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
Figure 15.19: Pipeline Product Portfolio: Bluebird Bio, Inc.
Figure 15.20: Bluebird Bio Inc: Overall Financials, 2017-2019
Figure 15.21: Bluebird Bio Inc: R&D Expenditure, 2017-2019
Figure 15.22: bluebird bio, Inc.: SWOT Analysis
Figure 15.23: Castle Creek Biosciences, Inc.: Overall Product Portfolio
Figure 15.24: Castle Creek Biosciences, Inc.: Pipeline Product Portfolio
Figure 15.25: Castle Creek Biosciences, Inc.: R&D Expenditure, 2017-2018
Figure 15.26: Castle Creek Biosciences, Inc.: SWOT Analysis
Figure 15.27: Dendreon Pharmaceuticals LLC: Product Portfolio
Figure 15.28: Dendreon Pharmaceuticals LLC.: SWOT Analysis
Figure 15.29: Helixmith Co., Ltd.: Pipeline Product Portfolio
Figure 15.30: ViroMed Co: Overall Financials, 2016-2018
Figure 15.31: Helixmith Co., Ltd.: SWOT Analysis
Figure 15.32: Human Stem Cell Institute: Overall Product Portfolio
Figure 15.33: Human Stem Cell Institute: SWOT Analysis
Figure 15.34: Kite Pharma, Inc: Overall Product Portfolio
Figure 15.35: Kite Pharma, Inc.: Pipeline Product Portfolio
Figure 15.36: Kite Pharma, Inc: Overall Financials, 2017-2019
Figure 15.37: Kite Pharma, Inc: Revenue (by Segment), 2017-2019
Figure 15.38: Kite Pharma, Inc: Revenue (by Region), 2017-2019
Figure 15.39: Kite Pharma, Inc: R&D Expenditure, 2017-2019
Figure 15.40: Kite Pharma, Inc.: SWOT Analysis
Figure 15.41: Kolon TissueGene, Inc.: Pipeline Product Portfolio
Figure 15.42: Kolon TissueGene, Inc.: SWOT Analysis
Figure 15.43: Novartis AG: Overall Product Portfolio
Figure 15.44: Novartis AG: Pipeline Product Portfolio
Figure 15.45: Novartis AG: Overall Financials, 2017-2019
Figure 15.46: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 15.47: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 15.48: Novartis AG: R&D Expense, 2017-2019
Figure 15.49: Novartis AG: SWOT Analysis
Figure 15.50: Orchard Therapeutics plc.: Pipeline Product Portfolio
Figure 15.51: Orchard Therapeutics plc.: Overall Financials, 2016-2018
Figure 15.52: Orchard Therapeutics plc: SWOT Analysis
Figure 15.53: Pfizer, Inc.: Pipeline Product Portfolio
Figure 15.54: Pfizer Inc.: Overall Financials, 2017-2019
Figure 15.55: Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 15.56: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 15.57: Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 15.58: Pfizer Inc: R&D Expenditure, 2017-2019
Figure 15.59: Pfizer, Inc.: SWOT Analysis
Figure 15.60: Renova Therapeutics: Pipeline Product Portfolio
Figure 15.61: Renova Therapeutics: SWOT Analysis
Figure 15.62: Spark Therapeutics, Inc.: Overall Product Portfolio
Figure 15.63: Spark Therapeutics, Inc.: Pipeline Product Portfolio
Figure 15.64: Spark Therapeutics, Inc.: Overall Financials, 2015-2017
Figure 15.65: Spark Therapeutics, Inc.: R&D Expenditure, 2015-2017
Figure 15.66: Spark Therapeutics, Inc.: SWOT Analysis
Figure 15.67: uniQure N.V.: Pipeline Product Portfolio
Figure 15.68: uniQure N.V.: SWOT Analysis
Figure 15.69: Vericel Corporation: Overall Product Portfolio
Figure 15.70: Vericel Corporation: Pipeline Product Portfolio
Figure 15.71: Vericel Corporation: Overall Financials, 2016-2018
Figure 15.72: Vericel Corporation: Revenue (by Product), 2016-2018
Figure 15.73: Vericel Corporation: R&D Expenditure (2016-2018)
Figure 15.74: Vericel Corporation: SWOT Analysis

Samples

Companies Mentioned

• Amgen Inc.
• Bausch & Lomb Incorporated
• Becton, Dickinson and Company
• Bluebird bio, Inc.
• Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
• Dendreon Pharmaceuticals LLC
• Helixmith Co., Ltd (ViroMed Co., Ltd)
• Human Stem Cells Institute
• Kite Pharma, Inc.
• Kolon TissueGene, Inc.
• Novartis AG
• Orchard Therapeutics plc.
• Pfizer, Inc.
• Renova Therapeutics
• Spark Therapeutics, Inc.
• uniQure N.V.
• Vericel Corporation